CD274 and melanoma: In this regard, the PD-1 inhibitors nivolumab, pembrolizumab, cemiplimab, dostarlimab and the PD-L1 inhibitors atezolizumab, avelumab and durvalumab have been authorised by the FDA for the treatment of melanoma, non-small-cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma and triple-negative breast cancer.